Letrozole Femara High Purity Antiestrogen Anti Cancer Healthy
CAS 112809-51-5 Letrozole
Alias: Femara, Lelrozol, TROZET,Letroz,Lelroz, letrozolex
CAS Registry Number:112809-51-5
Appearance: White crystalline powder.
Letrozole is a new generation of highly selective aromatase inhibitors, synthetic triazole derivatives, by inhibiting the aromatase, so that estrogen levels, thereby eliminating the estrogen on tumor growth stimulating effect. In vivo activity than the first generation of aromatase inhibitor aminomitol 150-250 times stronger. Because of its high selectivity, does not affect glucocorticoid, mineralocorticoid and thyroid function, high-dose use of adrenal corticosteroid secretion of non-inhibitory effect, and therefore has a high therapeutic index. The pre-clinical studies have shown that letrozole on the body of the system and the target organ is not potentially toxic, non-mutagenic and carcinogenic effects, and toxicity of small, well tolerated, and other aromatase inhibitors and anti- Estrogen drugs, the anti-tumor effect stronger. For the treatment of advanced breast cancer after anti-estrogen therapy ineffective in patients with postmenopausal breast cancer and early treatment.
Letrozoles are non suicidal Aromatase Inhibitors, belonging to the third generation of aromatase inhibitors. They are administered orally and hold the approval of the Food and Drug Administration of the United States (FDA) for use in treating two particular kinds of breast cancer. One is the case when hormone receptor positive breast cancer develops locally or is contracted through metastatis. The other is a similar case but when the cancer is of the estrogen receptor unknown category.
The estrogen receptor unknown category refers to those breast cancer conditions where the role of estrogens can not be determined with certainty. In these cases, it is impossible to predict if estrogen caused the cancer in the first place or if it would complicate and worsen the cancer further. Letrozoles are used in the treatment of such cancer conditions in post menopausal women. It is however rare that Letrozole be required for treating the post menopausal estrogen receptor unknown cancer, first-line. In most cases, it is used only after the usual first-line treatments using Selective Estrogen Receptor Modulator drugs like the Nolvadex have failed to show any positive effects.
Letrozole is a powerful Aromatase Inhibitor that was developed to fight breast cancer. For athletes and bodybuilders, it is a drug used to combat the estrogenic side effects of anabolic steroids water-retention, acne and gynocomastia. It will also raise testosterone levels because of the lowered estrogen in the body. Side effects from Letrozole include a lowered sex drive and continuous use can lead to lowered lipid function and an impaired immune system.
Dosages and Half Life
The half life is approximately 2-4 days. Dosages vary quite a bit, 0.25mg up to 1mg every day or every other day is a good starting dose. It’s best to be conservative with the dosage because if you overdose the sides can be harsh.
|Contact Person :||Lisa|